Abstract

The effect of taxifolin on cisplatin-induced oxidative pulmonary damage was investigated biochemically and histopathologically in male albino Wistar rats. There were four groups, with six animals in each group: 50 mg/kg of taxifolin plus 2.5 mg/kg of cisplatin (TC) group, 2.5 mg/kg of cisplatin only (CIS) group, 50 mg/kg of taxifolin only (TG) group, and a healthy control group (HG). In terms of the experimental procedure, the animals in the TC and TG groups were first treated via oral gavage. The CIS and HG groups received distilled water as solvent, respectively. One hour later, the TC and CIS groups received cisplatin at a dose of 2.5 mg/kg (injected intraperitoneally). Taxifolin, cisplatin, and the distilled water were administered at the indicated dose and volume, using the same method daily for 14 d. At the end of this period, the animals were killed with a high dosage of thiopental anaesthesia (50 mg/kg). Blood and lung tissue samples were taken for biochemical (malondialdehyde (MDA), myeloperoxidase (MPO), total glutathione (tGSH), and 8-hydroxy-2 deoxyguanosine (8-OHdG)) analyses and histopathological examinations. The biochemical and histopathological results in the TC and HG groups were then compared with those in the CIS group. Cisplatin increased the levels of MDA, myeloperoxidase, and 8-OHdG, a marker of oxidative DNA damage, and reduced the amount of tGSH in the lung tissue. Moreover, severe alveolar damage, including oedema and extensive alveolar septal fibrosis, in addition to infiltration of polymorphic nuclear leucocytes and haemorrhagic foci, was observed in the CIS group. These histopathological findings demonstrate that taxifolin provides protection against pulmonary oxidative stress by preventing increases in oxidant parameters and decreases in antioxidants.

Highlights

  • Cisplatin is a platinum compound and antineoplastic drug, with broad-spectrum activity against various solid cancers [1, 2]

  • Interstitial inflammation, fibrosis, structural pulmonary damage, and other severe complications have been reported during cisplatin chemotherapy [5]

  • These adverse effects of cisplatin-induced pulmonary damage have been attributed to increased lipid peroxidation caused by free oxygen radicals and decreases in antioxidant parameters [6]

Read more

Summary

Introduction

Cisplatin (cis-dichlorodiammine platinum II) is a platinum compound and antineoplastic drug, with broad-spectrum activity against various solid cancers [1, 2]. Interstitial inflammation, fibrosis, structural pulmonary damage, and other severe complications have been reported during cisplatin chemotherapy [5]. These adverse effects of cisplatin-induced pulmonary damage have been attributed to increased lipid peroxidation caused by free oxygen radicals and decreases in antioxidant parameters [6]. The authors reported oxidative DNA damage in the lung tissue of a cisplatin-treated group [8]. In this group, the levels of total oxidants were high, whereas those of antioxidants were low [8]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call